Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -0.63% | |
| Wide Bands | Range Expansion | -3.64% | |
| Gapped Down | Weakness | -3.64% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.02% | |
| Inside Day | Range Contraction | -7.02% | |
| Wide Bands | Range Expansion | -7.02% | |
| Up 3 Days in a Row | Strength | -7.02% |
| Alert | Time |
|---|---|
| Down 3% | about 19 hours ago |
| Possible NR7 | about 20 hours ago |
| 20 DMA Support | about 22 hours ago |
| Fell Below Previous Day's Low | about 22 hours ago |
| Down 2 % | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.75 |
| 52 Week Low | 1.26 |
| Average Volume | 114,771 |
| 200-Day Moving Average | 2.37 |
| 50-Day Moving Average | 1.73 |
| 20-Day Moving Average | 1.57 |
| 10-Day Moving Average | 1.64 |
| Average True Range | 0.15 |
| RSI (14) | 47.92 |
| ADX | 20.78 |
| +DI | 20.01 |
| -DI | 15.17 |
| Chandelier Exit (Long, 3 ATRs) | 1.55 |
| Chandelier Exit (Short, 3 ATRs) | 1.70 |
| Upper Bollinger Bands | 1.78 |
| Lower Bollinger Band | 1.36 |
| Percent B (%b) | 0.55 |
| BandWidth | 27.21 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0169 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.76 | ||||
| Resistance 3 (R3) | 1.76 | 1.71 | 1.73 | ||
| Resistance 2 (R2) | 1.71 | 1.67 | 1.71 | 1.72 | |
| Resistance 1 (R1) | 1.65 | 1.64 | 1.63 | 1.65 | 1.71 |
| Pivot Point | 1.60 | 1.60 | 1.59 | 1.60 | 1.60 |
| Support 1 (S1) | 1.54 | 1.56 | 1.52 | 1.54 | 1.47 |
| Support 2 (S2) | 1.49 | 1.53 | 1.49 | 1.46 | |
| Support 3 (S3) | 1.43 | 1.49 | 1.45 | ||
| Support 4 (S4) | 1.43 |
